There is a significant untapped potential in the vaccine market. Unmet needs still exist because many diseases still have a lower immune rate, or no vaccine is available. Financial analysts expect the market to reach US $39 billion by 2015. WHO predicts that the global market will increase to $100 billion by 2025, and 120 new products will be launched in the next 10 years.
The increase in the price level reflects the enhancement of innovation: part of the growth of the vaccine industry comes from the higher prices charged by the newly emerging vaccine products based on the value they offer (see below). Wyeth launched Prevnar-7 in 2000, which is more expensive than the sum of most other children's vaccines, while still showing high cost. The Merck Co's human papillomavirus vaccine Gardasil was priced at nearly $400 when it was launched in 2006. With the increase in the value of six additional vaccines, the Pfizer Inc launched Prevnar-13, which costs about $513 a course.
Industry growth has led to massive mergers and Acquisitions: many large manufacturers have begun to use vaccines to drive sustained growth and brand revenue. In 2010, there were 195 vaccine cooperation transactions in the industry, including the acquisition of Johnson by the company, which reached $2 billion 300 million for the introduction of the child vaccine, local vaccine and travel vaccine assets of the medium size vaccine manufacturer to Johnson.